We are live on ! Find out more
ERNA icon

Eterna Therapeutics
ERNA

9 hedge funds and large institutions have $91.7K invested in Eterna Therapeutics in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

2.17% less ownership

Funds ownership: 2.85% → 0.68% (-2.2%)

55% less funds holding

Funds holding: 20 → 9 (-11)

65% less capital invested

Capital invested by funds: $264K → $91.7K (-$173K)

92% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 12

Holders
9
Holders Change
-11
Holders Change %
-55%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
1
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCA
Sippican Capital Advisors
Massachusetts
+$13.4K
2
Morgan Stanley
Morgan Stanley
New York
+$1.58K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.51K

Top Sellers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
-$40.8K
2
Citigroup
Citigroup
New York
-$27.3K
3
CPWM
Cypress Point Wealth Management
Texas
-$16.8K
4
Vanguard Personalized Indexing Management
Vanguard Personalized Indexing Management
California
-$12K
5
Citadel Advisors
Citadel Advisors
Florida
-$11.7K

ERNA Hedge Fund Activity: Q2 2025 in Review

9 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q2 2025, worth a combined $91.7K — down 65% from $264K a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of ERNA and 1 opened new positions — a net loss of 11 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was Sippican Capital Advisors, adding an estimated $13.4K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $40.8K sold.

  • 9 institutional investors held Eterna Therapeutics (ERNA) as of Q2 2025, down from 20 in Q1 2025.
  • Funds reported $91.7K of Eterna Therapeutics stock for Q2 2025, down 65% quarter-over-quarter.
  • 1 fund opened new Eterna Therapeutics positions in Q2 2025 and 12 closed out, a net change of -11 holders.
  • The largest Eterna Therapeutics buyer in Q2 2025 was Sippican Capital Advisors, an estimated $13.4K added.
  • The largest Eterna Therapeutics seller in Q2 2025 was Two Sigma Securities, an estimated $40.8K sold.

Based on aggregated 13F filings for Q2 2025.